171 related articles for article (PubMed ID: 24858462)
1. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).
Pillai RN; Aisner J; Dahlberg SE; Rogers JS; DiPaola RS; Aisner S; Ramalingam SS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):177-83. PubMed ID: 24858462
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Song M; DiPaola RS; Cracchiolo BM; Gibbon DG; Hellmann M; Nieves-Neira W; Vaidya A; Wagreich AR; Shih WJ; Rodriguez-Rodriguez L
Int J Gynecol Cancer; 2014 Nov; 24(9):1636-41. PubMed ID: 25304678
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
Jalal S; Bedano P; Einhorn L; Bhatia S; Ansari R; Bechar N; Koneru K; Govindan R; Wu J; Yu M; Schneider B; Hanna N
J Thorac Oncol; 2010 Dec; 5(12):2008-11. PubMed ID: 21102263
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
DiPaola RS; Chen YH; Stein M; Vaughn D; Patrick-Miller L; Carducci M; Roth B; White E; Wilding G
J Transl Med; 2010 Feb; 8():20. PubMed ID: 20178647
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.
DiPaola RS; Rafi MM; Vyas V; Toppmeyer D; Rubin E; Patel J; Goodin S; Medina M; Medina P; Zamek R; Zhang C; White E; Gupta E; Hait WN
J Clin Oncol; 1999 Jul; 17(7):2213-8. PubMed ID: 10561278
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Ramalingam SS; Foster J; Gooding W; Evans T; Sulecki M; Belani CP
Cancer; 2010 Mar; 116(5):1344-9. PubMed ID: 20082454
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Mountzios G; Emmanouilidis C; Vardakis N; Kontopodis E; Hatzidaki D; Popis E; Karachaliou N; Kotsakis A; Agelidou M; Georgoulias V
Lung Cancer; 2012 Jul; 77(1):146-50. PubMed ID: 22418242
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Gelsomino F; Tiseo M; Barbieri F; Riccardi F; Cavanna L; Frassoldati A; Delmonte A; Longo L; Dazzi C; Cinieri S; Colantonio I; Sperandi F; Lamberti G; Brocchi S; Tofani L; Boni L; Ardizzoni A
Br J Cancer; 2020 Jul; 123(1):26-32. PubMed ID: 32346071
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
Yun T; Kim HT; Han JY; Yoon SJ; Kim HY; Nam BH; Lee JS
Cancer Res Treat; 2016 Apr; 48(2):465-72. PubMed ID: 26044164
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
Skeel RT; Huang J; Manola J; Wilding G; Dreicer R; Walker P; Muggia F; Crawford ED; Dutcher JP; Loehrer PJ
Cancer Invest; 2003; 21(1):41-6. PubMed ID: 12643008
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
17. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Sarma RP; Johnson DH
J Clin Oncol; 1995 Jun; 13(6):1430-5. PubMed ID: 7751889
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
